These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Pharmacologic characterization of BMS-191095, a mitochondrial K(ATP) opener with no peripheral vasodilator or cardiac action potential shortening activity. Grover GJ; D'Alonzo AJ; Garlid KD; Bajgar R; Lodge NJ; Sleph PG; Darbenzio RB; Hess TA; Smith MA; Paucek P; Atwal KS J Pharmacol Exp Ther; 2001 Jun; 297(3):1184-92. PubMed ID: 11356945 [TBL] [Abstract][Full Text] [Related]
7. The cardioprotective and electrophysiological effects of cromakalim are attenuated by meclofenamate through a cyclooxygenase-independent mechanism. Grover GJ; D'Alonzo AJ; Sleph PG; Dzwonczyk S; Hess TA; Darbenzio RB J Pharmacol Exp Ther; 1994 May; 269(2):536-40. PubMed ID: 8182522 [TBL] [Abstract][Full Text] [Related]
8. ATP sensitive potassium channel openers are of potential benefit in ischaemic heart disease. Cavero I; Premmereur J Cardiovasc Res; 1994 Jan; 28(1):32-3. PubMed ID: 8111790 [No Abstract] [Full Text] [Related]
9. Modulation of ATP-sensitive K+ channel activity and contractile behavior in mammalian ventricle by the potassium channel openers cromakalim and RP49356. Ripoll C; Lederer WJ; Nichols CG J Pharmacol Exp Ther; 1990 Nov; 255(2):429-35. PubMed ID: 2243335 [TBL] [Abstract][Full Text] [Related]
10. Effects of cromakalim and glibenclamide on myocardial high energy phosphates and intracellular pH during ischemia-reperfusion: 31P NMR studies. Docherty JC; Gunter HE; Kuzio B; Shoemaker L; Yang L; Deslauriers R J Mol Cell Cardiol; 1997 Jun; 29(6):1665-73. PubMed ID: 9220352 [TBL] [Abstract][Full Text] [Related]
11. Cardioselective antiischemic ATP-sensitive potassium channel openers. 4. Structure-activity studies on benzopyranylcyanoguanidines: replacement of the benzopyran portion. Atwal KS; Ferrara FN; Ding CZ; Grover GJ; Sleph PG; Dzwonczyk S; Baird AJ; Normandin DE J Med Chem; 1996 Jan; 39(1):304-13. PubMed ID: 8568821 [TBL] [Abstract][Full Text] [Related]
12. Effects of the KATP channel opener bimakalim on coronary blood flow, monophasic action potential duration, and infarct size in dogs. Yao Z; Gross GJ Circulation; 1994 Apr; 89(4):1769-75. PubMed ID: 8149542 [TBL] [Abstract][Full Text] [Related]
14. ATP-sensitive potassium channels and skeletal muscle function in vitro. Weselcouch EO; Sargent C; Wilde MW; Smith MA J Pharmacol Exp Ther; 1993 Oct; 267(1):410-6. PubMed ID: 8229769 [TBL] [Abstract][Full Text] [Related]
15. Potassium channel modulation: a new drug principle for regulation of smooth muscle contractility. Studies on isolated airways and arteries. Nielsen-Kudsk JE Dan Med Bull; 1996 Dec; 43(5):429-47. PubMed ID: 8960816 [TBL] [Abstract][Full Text] [Related]
16. Anti-ischemic effects of the potassium channel activators pinacidil and cromakalim and the reversal of these effects with the potassium channel blocker glyburide. Grover GJ; McCullough JR; Henry DE; Conder ML; Sleph PG J Pharmacol Exp Ther; 1989 Oct; 251(1):98-104. PubMed ID: 2507775 [TBL] [Abstract][Full Text] [Related]
17. Diabetes and ATP-sensitive potassium channel openers and blockers in isolated ischemic/reperfused hearts. Tosaki A; Engelman DT; Engelman RM; Das DK J Pharmacol Exp Ther; 1995 Dec; 275(3):1115-23. PubMed ID: 8531071 [TBL] [Abstract][Full Text] [Related]
18. Cardioprotection in ischemic rat hearts with the SH-containing angiotensin-converting enzyme inhibitor zofenopril: possible involvement of the ATP-sensitive potassium channel. Sargent CA; Sleph PG; Dzwonczyk S; Smith MA; Normandin D; Antonaccio MJ; Grover GJ J Pharmacol Exp Ther; 1993 May; 265(2):609-18. PubMed ID: 8496812 [TBL] [Abstract][Full Text] [Related]